Improved care of rhabdomyosarcoma in Jordan using less intensive therapy

Pediatric Blood and Cancer

Volumn 60, Issue 1, 2013, Pages 53-58

  Al Jumaily, Usama ^a   Ayyad, Omar ^a   Masarweh, Main ^a   Ghandour, Khalil ^a   Almousa, Abdelatif ^a   Al Hussaini, Maysa ^a   Ferrari, Andrea ^b   Sultan, Iyad ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cyclophosphamide; Developing countries; Rhabdomyosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFANT; JORDAN; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; JORDAN; MALE; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA;

EID: 84870156788     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24241     Document Type: Article

References (28)

1. Caillaud JM, Gerard-Marchant R, Marsden HB, et al. Histopathological classification of childhood rhabdomyosarcoma: A report from the International Society of Pediatric Oncology pathology panel. Med Pediatr Oncol 1989; 17: 391-400.
2. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995; 13: 2123-2139.
3. Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001; 5: 9-15.
4. Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002; 38: 22-32.
5. Wharam MD, Jr. Rhabdomyosarcoma of parameningeal sites. Semin Radiat Oncol 1997; 7: 212-216.
6. Oberlin O, Rey A, Anderson J, et al. Treatment of orbital rhabdomyosarcoma: Survival and late effects of treatment-results of an international workshop. J Clin Oncol 2001; 19: 197-204.
7. Antillon F, Castellanos M, Valverde P, et al. Treating pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer 2008; 51: 760-764.
8. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61: 209-220.
9. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-3102.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
11. Halalsheh H, Abuirmeileh N, Rihani R, et al. Outcome of childhood acute lymphoblastic leukemia in Jordan. Pediatr Blood Cancer 2011; 57: 385-391.
12. Sultan I, Wilson MW, Nawaiseh I, et al. Enucleation for retinoblastoma: The experience of a single center in Jordan. Int Ophthalmol 2010; 30: 407-414.
13. Sultan I, Masarweh M, Ismael T, et al. From upfront nephrectomy to preoperative chemotherapy and back: A single institution experience in the treatment of Wilms tumor. J Pediatr Hematol Oncol 2009; 31: 333-338.
14. Schmidt BF. The 3rd Intergroup Rhabdomyosarcoma Study (IRS III). Strahlenther Onkol 1996; 172: 231-233.
15. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610-630.
16. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71: 1904-1922.
17. Treuner J, Kuhl J, Beck J, et al. New aspects in the treatment of childhood rhabdomyosarcoma: Results of the German Cooperative Soft-Tissue Sarcoma Study (CWS-81). Prog Pediatr Surg 1989; 22: 162-173.
18. Raney B, Anderson J, Breneman J, et al. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: Report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51: 17-22.
19. Raney RB, Chintagumpala M, Anderson J, et al. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer 2008; 50: 958-964.
20. Raney RB, Stoner JA, Walterhouse DO, et al. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: A report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Pediatr Blood Cancer 2004; 42: 618-625.
21. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21: 78-84.
22. Bisogno G, De Rossi C, Gamboa Y, et al. Improved survival for children with parameningeal rhabdomyosarcoma: Results from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer 2008; 50: 1154-1158.
23. Rodeberg DA, Anderson JR, Arndt CA, et al. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma (RMS) of the bladder/Prostate (BP): Combined results from the children's oncology group (COG), German cooperative soft tissue sarcoma study (CWS), Italian cooperative group (ICG), and international society of pediatric oncology (SIOP) malignant mesenchymal tumors (MMT) committee. Int J Cancer 2010; 128: 1232-1239.
24. Ferrari A, Bisogno G, Casanova M, et al. Paratesticular rhabdomyosarcoma: Report from the Italian and German Cooperative Group. J Clin Oncol 2002; 20: 449-455.
25. Ruymann FB, Vietti T, Gehan E, et al. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol 1995; 17: 331-337.
26. Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000; 18: 2427-2434.
27. Spunt SL, Smith LM, Ruymann FB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the soft tissue sarcoma committee of the children's oncology group. Clin Cancer Res 2004; 10: 6072-6079.
28. Malempati S, Hawkins DS. Rhabdomyosarcoma: Review of the children's oncology group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012; 59: 5-10.